Overview: Anti-NMDA Antibody TestIntroduction: The Anti-NMDA Antibody Test detects antibodies linked to autoimmune encephalitis, which may cause seizures, memory loss, or behavioral changes. Aligned with 2023 AAN guidelines, it uses an immunoassay for high specificity, aiding in autoimmune screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected autoimmune encephalitis.
Other Names: Anti-NMDA Assay, NMDA Receptor Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Autoimmune encephalitis testing advanced in the 2000s with antibody discovery. Anti-NMDA assays emerged in the 2010s, and by the 2020s, immunoassays improved detection of neurological disorders.
Purpose: Diagnoses autoimmune encephalitis, guides treatment, and monitors disease activity in patients with seizures, memory loss, or behavioral changes.
Test Parameters: 1. Anti NMDA Receptor Antibody
Pretest Condition: No fasting required. Collect serum, CSF, or saliva at any time. Report symptoms like seizures or behavioral changes, and list medications like immunosuppressants.
Specimen: 2-5 mL serum (SST), 1-2 mL CSF (sterile container), or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document neurological symptoms, autoimmune disease history, or family history of neurological disorders. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for immunosuppressive therapy or imaging.
Procedural Considerations: Uses an immunoassay to measure anti-NMDA antibodies. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Immunosuppressants may suppress antibody levels, causing false negatives. Hemolysis or improper storage can degrade samples.
Clinical Significance: Positive results confirm autoimmune encephalitis, prompting immunosuppressive therapy. Negative results may require other antibody tests.
Specialist Consultation: Consult a neurologist for result interpretation. An autoimmune neurologist referral is advised for complex cases.
Additional Supporting Tests: Anti-IgLON-5 test, brain MRI, or CSF analysis to confirm autoimmune encephalitis or assess disease extent.
Test Limitations: False negatives may occur with early disease or immunosuppressive therapy. Results require clinical correlation.
References: AAN Autoimmune Encephalitis Guidelines, 2023; Neurology, Dalmau J, 2022.
